CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript Summary
CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript Summary
GAAP net loss for Q2 2024 was $4.2 million, a decline from a net income of $5.8 million in Q2 2023, largely impacted by the absence of milestone payments received in the previous year.The following is a summary of the CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript:
以下是CollPlant Biotechnologies Ltd. (CLGN) Q2 2024業績會議電話記錄摘要：
Financial Performance:
金融業績：
CollPlant reported a significant decrease in Q2 2024 GAAP revenues to $249,000, down from $10.2 million in Q2 2023, primarily due to the milestone payment from AbbVie in the previous year.
GAAP gross loss for Q2 2024 was $287,000, contrasting with a gross profit of $9.6 million in Q2 2023.
GAAP net loss for Q2 2024 was $4.2 million, a decline from a net income of $5.8 million in Q2 2023, largely impacted by the absence of milestone payments received in the previous year.
Collplant報告稱，由於前一年度AbbVie的里程碑款，Q2 2024 GAAP收入大幅下降至249,000美元，低於2023年Q2的一千零二十萬美元。
2024年Q2 GAAP毛虧損爲287,000美元，而2023年Q2的毛利潤爲960萬美元。
2024年Q2 GAAP淨虧損爲420萬美元，較2023年Q2的淨利潤580萬美元下降，主要原因是前一年度未獲得里程碑款的影響。
Business Progress:
業務進展：
CollPlant is advancing its novel breast implant and dermal filler programs, including ongoing preclinical studies for the regenerative breast implant product with a focus on commercial size 200 cc volume implants and collaborations with AbbVie on a clinical-phase dermal filler product.
The company emphasized innovation in regenerative medicine, with further development in photocurable dermal fillers and the issuance of patents in multiple regions.
CollPlant released its first environmental, social and governance report, outlining its corporate sustainability strategy with initiatives like reducing emissions and sustainable sourcing.
Collplant正在推進其新型乳房植入物和皮下填充物計劃，包括針對200毫升商業用植入物的再生乳房植入產品的不斷進行的臨床前研究以及與AbbVie合作的臨床階段皮下填充物產品。
公司強調再生醫學的創新，在光固化皮下填充物的進一步開發以及在多個地區頒發專利方面取得了進展。
Collplant發佈了其首份環境、社會和治理報告，概述了其企業可持續發展戰略，包括減少排放和可持續採購等舉措。
Opportunities:
機會：
The global breast implant market, estimated to grow to $6.5 billion by 2033, presents a significant opportunity for CollPlant's regenerative breast implant product, projected to offer safety and performance improvements over existing implants.
The reinvigoration of the dermal filler market indicates potential growth opportunities for CollPlant's innovative dermal filler products, which apart from filling, are expected to provide regenerative properties extending their market potential.
全球乳房植入市場有望在2033年增長至65億美元，這爲Collplant的再生性乳房植入產品提供了巨大機遇，並預計將在現有植入物的安全性和性能上進行改進。
皮下填充物市場的復甦表明CollPlant的創新型皮下填充物產品具有潛在的增長機會，除填充作用外，預計還可以提供再生性能以擴大市場潛力。
Risks:
風險：
The gradual growth and commercialization of the AI technologies present a potential risk, should there be any delays or unforeseen complications in product efficacy or regulatory approvals.
人工智能技術的逐步增長和商業化存在潛在風險，如果產品效能或監管審批出現延誤或未預見的複雜情況，則可能會對公司造成影響。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
